Imatinib is a protein kinase inhibitor which binds to a specific amino acid residue within the ATP binding pocket and the activation loop.
In human medicine, this drug has shown efficacy against leukemia, although drug resistance is an emerging phenomenon.
The usual starting dose of Imatinib is 20 mg/kg per day.
Large trials of low-dose versus high-dose imatinib in humans did not improve overall survival.
- Kim JH et al (2012) Combined treatment of 3-hydroxyflavone and imatinib mesylate increases apoptotic cell death of imatinib mesylate-resistant leukemia cells. Leuk Res 36(9):1157-1164
- Dickerson EB et al (2013) Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-β and Src in Tumor Growth. Transl Oncol 6(2):158-168
- Hadzijusufovic E et al (2012) NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation. Allergy 67(7):858-868
- Kobayashi M et al (2012) Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy. Vet J 193(1):264-267
- de Matteo RP et al (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373(9669)':1097–1104